147 related articles for article (PubMed ID: 18221542)
21. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.
Mahipal A; Terai M; Berd D; Chervoneva I; Patel K; Mastrangelo MJ; Sato T
Cancer Immunol Immunother; 2011 Jul; 60(7):1039-45. PubMed ID: 21519827
[TBL] [Abstract][Full Text] [Related]
22. Antigen-independent immune responses after dendritic cell vaccination.
Leonhartsberger N; Ramoner R; Putz T; Gander H; Rahm A; Falkensammer C; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2007 Jun; 56(6):897-903. PubMed ID: 17106716
[TBL] [Abstract][Full Text] [Related]
23. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells.
Kyte JA; Kvalheim G; Lislerud K; thor Straten P; Dueland S; Aamdal S; Gaudernack G
Cancer Immunol Immunother; 2007 May; 56(5):659-75. PubMed ID: 16947019
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma.
Sussman TA; Severgnini M; Giobbie-Hurder A; Friedlander P; Swanson SJ; Jaklitsch M; Clancy T; Goguen LA; Lautz D; Swanson R; Daley H; Ritz J; Dranoff G; Hodi FS
Front Oncol; 2024; 14():1395978. PubMed ID: 38812776
[TBL] [Abstract][Full Text] [Related]
25. Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.
Palma M; Adamson L; Hansson L; Kokhaei P; Rezvany R; Mellstedt H; Osterborg A; Choudhury A
Cancer Immunol Immunother; 2008 Nov; 57(11):1705-10. PubMed ID: 18663443
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial.
Hernando JJ; Park TW; Kübler K; Offergeld R; Schlebusch H; Bauknecht T
Cancer Immunol Immunother; 2002 Mar; 51(1):45-52. PubMed ID: 11845259
[TBL] [Abstract][Full Text] [Related]
27. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
Svane IM; Pedersen AE; Johansen JS; Johnsen HE; Nielsen D; Kamby C; Ottesen S; Balslev E; Gaarsdal E; Nikolajsen K; Claesson MH
Cancer Immunol Immunother; 2007 Sep; 56(9):1485-99. PubMed ID: 17285289
[TBL] [Abstract][Full Text] [Related]
28. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.
Poschke I; Mao Y; Adamson L; Salazar-Onfray F; Masucci G; Kiessling R
Cancer Immunol Immunother; 2012 Jun; 61(6):827-38. PubMed ID: 22080405
[TBL] [Abstract][Full Text] [Related]
29. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.
Maio M; Fonsatti E; Lamaj E; Altomonte M; Cattarossi I; Santantonio C; Melani C; Belli F; Arienti F; Colombo MP; Parmiani G
Cancer Immunol Immunother; 2002 Mar; 51(1):9-14. PubMed ID: 11845255
[TBL] [Abstract][Full Text] [Related]
30. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.
Osada T; Clay T; Hobeika A; Lyerly HK; Morse MA
Cancer Immunol Immunother; 2006 Sep; 55(9):1122-31. PubMed ID: 16273350
[TBL] [Abstract][Full Text] [Related]
31. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters.
Engell-Noerregaard L; Hansen TH; Andersen MH; Thor Straten P; Svane IM
Cancer Immunol Immunother; 2009 Jan; 58(1):1-14. PubMed ID: 18719915
[TBL] [Abstract][Full Text] [Related]
32. High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function.
Pizzurro GA; Madorsky Rowdo FP; Pujol-Lereis LM; Quesada-Allué LA; Copati AM; Roberti MP; Teillaud JL; Levy EM; Barrio MM; Mordoh J
Cancer Immunol Immunother; 2013 Jan; 62(1):3-15. PubMed ID: 22722447
[TBL] [Abstract][Full Text] [Related]
33. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.
Bol KF; Figdor CG; Aarntzen EH; Welzen ME; van Rossum MM; Blokx WA; van de Rakt MW; Scharenborg NM; de Boer AJ; Pots JM; Olde Nordkamp MA; van Oorschot TG; Mus RD; Croockewit SA; Jacobs JF; Schuler G; Neyns B; Austyn JM; Punt CJ; Schreibelt G; de Vries IJ
Oncoimmunology; 2015 Aug; 4(8):e1019197. PubMed ID: 26405571
[TBL] [Abstract][Full Text] [Related]
34. Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome.
Venanzi FM; Petrini M; Fiammenghi L; Bolli E; Granato AM; Ridolfi L; Gabrielli F; Barucca A; Concetti A; Ridolfi R; Riccobon A
Cancer Immunol Immunother; 2010 Jan; 59(1):27-34. PubMed ID: 19440709
[TBL] [Abstract][Full Text] [Related]
35. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial.
Pecher G; Häring A; Kaiser L; Thiel E
Cancer Immunol Immunother; 2002 Dec; 51(11-12):669-73. PubMed ID: 12439613
[TBL] [Abstract][Full Text] [Related]
36. Combining chemotherapy and autologous peptide-pulsed dendritic cells provides survival benefit in stage IV melanoma patients.
Eisendle K; Weinlich G; Ebner S; Forstner M; Reider D; Zelle-Rieser C; Tripp CH; Fritsch P; Stoitzner P; Romani N; Nguyen VA
J Dtsch Dermatol Ges; 2020 Nov; 18(11):1270-1277. PubMed ID: 33197129
[TBL] [Abstract][Full Text] [Related]
37. Intradermal naked DNA vaccination by DNA tattooing for mounting tumor-specific immunity in stage IV melanoma patients: a phase I clinical trial.
Geukes Foppen MH; Rohaan MW; Borgers JSW; Philips D; Vyth-Dreese F; Beijnen JH; Nuijen B; van den Berg JH; Haanen JBAG
Oncol Res Treat; 2024 Apr; ():. PubMed ID: 38583422
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Survival and Immune Response Dynamics in Melanoma Patients Undergoing TAPCells-Based Vaccination Therapy.
Tittarelli A; Pereda C; Gleisner MA; López MN; Flores I; Tempio F; Lladser A; Achour A; González FE; Durán-Aniotz C; Miranda JP; Larrondo M; Salazar-Onfray F
Vaccines (Basel); 2024 Mar; 12(4):. PubMed ID: 38675738
[TBL] [Abstract][Full Text] [Related]
39. Letter to the Editor in Response to: Complete Resection of Necrotic Bowel Improves Survival in NEC.
Kaya C; Karabulut R; Turkyilmaz Z; Sonmez K
J Pediatr Surg; 2024 Mar; ():. PubMed ID: 38561307
[No Abstract] [Full Text] [Related]
40. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
Romano E; Michielin O; Voelter V; Laurent J; Bichat H; Stravodimou A; Romero P; Speiser DE; Triebel F; Leyvraz S; Harari A
J Transl Med; 2014 Apr; 12():97. PubMed ID: 24726012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
